Teva Pharmaceuticals said Monday, Nov. 2, it will stop its Phase 2 TOPAS-MSA study in adults with multiple system atrophy (MSA) after an interim review suggested it was unlikely to meet its main efficacy goal.
Teva is the U.S. affiliate of Teva Pharmaceutical Industries Ltd. The company said an independent data monitoring committee recommended ending the study after a planned review met a preset futility criterion. Teva said the analysis found no safety concerns. It described the result as a projection rather than a final assessment of emrusolmin’s efficacy, and did not disclose a numerical efficacy result, the threshold or the number of people reviewed.
The study assigned participants by chance to receive 300 mg of emrusolmin or placebo, with treatment assignments concealed from participants and study staff. Treatment lasted about 48 weeks, followed by a further four-week follow-up. Teva planned to enroll about 350 adults; ClinicalTrials.gov records 349 participants. Its “Last Update Posted” field was Oct. 7, 2026, when the registry listed the study as “Active, not recruiting.”
Teva plans to assess TOPAS-MSA results together with available information from a separate open-label extension study, then share its conclusions publicly. It has not given a timetable. The company said ending TOPAS-MSA does not decide the future of emrusolmin’s wider program, which it is pursuing with MODAG GmbH.
Teva describes emrusolmin as an experimental oral compound intended to affect alpha-synuclein aggregation, which the company says is involved in MSA. The National Institute of Neurological Disorders and Stroke (NINDS) says MSA is a progressive neurodegenerative disorder that can impair movement and automatic functions such as blood-pressure control and digestion.
Eric Hughes, M.D., Ph.D., Teva’s executive vice president of Global R&D and chief medical officer, said the company was “deeply committed to learning everything we can from these data.”
Teva’s next scheduled event is its third-quarter 2026 earnings call at 8 a.m. ET Tuesday, Nov. 3.
